Nutritional genomics era: Opportunities toward a genome-tailored nutritional regimen

Journal of Nutritional Biochemistry

Volumn 21, Issue 6, 2010, Pages 457-467

  Costa, Valerio ^a   Casamassimi, Amelia ^b   Ciccodicola, Alfredo ^a  

^a INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Gene polymorphisms; Gene nutrient interactions; Genetic testing; Nutrigenomics; Personalized nutrition

Indexed keywords

ANGIOTENSINOGEN; INTERLEUKIN 6; INTERLEUKIN 8; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D RECEPTOR;

BONE DENSITY; CANCER RISK; CANCER SUSCEPTIBILITY; CARDIOVASCULAR DISEASE; COPY NUMBER VARIATION; DNA METHYLATION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; HUMAN GENOME; HYPERTENSION; INFLAMMATION; LUNG CANCER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIGENOMICS; OBESITY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; DIET; FOOD; GENE EXPRESSION REGULATION; GENOMICS; HAPLOTYPE; HEALTH PROMOTION; LEGISLATION AND JURISPRUDENCE; NUTRITIONAL SCIENCE; PERSONALIZED MEDICINE;

DIET; DNA METHYLATION; FOOD; GENE EXPRESSION REGULATION; GENETIC TESTING; GENOMICS; HAPLOTYPES; HEALTH PROMOTION; HUMANS; INDIVIDUALIZED MEDICINE; NUTRITIONAL SCIENCES; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77952875978     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2009.10.012     Document Type: Review

References (157)

1. Kaput J., Rodriguez R.L. Nutritional genomics: the next frontier in the postgenomic era. Physiol Genomics 2004, 16:166-177.
2. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., et al. The sequence of the human genome. Science 2001, 291:1304-1351.
3. International Human Genome Sequencing Consortium Initial sequencing and analysis of the human genome. Nature 2001, 409:860-921.
4. International HapMap Consortium A haplotype map of the human genome. Nature 2005, 437:1299-1320.
5. Sachidanandam R., Weissman D., Schmidt S.C., Kakol J.M., Stein L.D., Marth G. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001, 409:928-933.
6. Livingston R.J., von Niederhausern A., Jegga A.G., Crawford D.C., Carlson C.S., Rieder M.J., et al. Pattern of sequence variation across 213 environmental response genes. Genome Res 2004, 14:1821-1831.
7. Kong A., Gudbjartsson D.F., Sainz J., Jonsdottir G.M., Gudjonsson S.A., Richardsson B., et al. A high-resolution recombination map of the human genome. Nat Genet 2002, 31:241-247.
8. Doria A., Patti M.E., Kahn C.R. The emerging genetic architecture of type 2 diabetes. Cell Metab 2008, 8:186-200.
9. Drake T.A., Schadt E.E., Lusis A.J. Integrating genetic and gene expression data: application to cardiovascular and metabolic traits in mice. Mamm Genome 2006, 17:466-479.
10. Grody W.W. Molecular genetic risk screening. Annu Rev Med 2003, 54:473-490.
11. Willett W.C. Balancing life-style and genomics research for disease prevention. Science 2002, 296:695-698.
12. Kaput J. Nutrigenomics research for personalized nutrition and medicine. Curr Opin Biotechnol 2008, 19:110-120.
13. Fay L.B., German J.B. Personalizing foods: is genotype necessary?. Curr Opin Biotechnol 2008, 19:121-128.
14. Ottman R. An epidemiological approach to gene-environment interaction. Genet Epidemiol 1990, 7:177-185.
15. Weinsier R.L., Hunter G.R., Heini A.F., Goran M.I., Sell S.M. The etiology of obesity: relative contribution of metabolic factors, diet, and physical activity. Am J Med 1998, 105:145-150.
16. Loos R.J., Bouchard C. Obesity is it a genetic disorder?. J Intern Med 2003, 254:401-425.
17. Leong N.M., Mignone L.I., Newcomb P.A., Titus-Ernstoff L., Baron J.A., Trentham-Dietz A., et al. Early life risk factors in cancer: the relation of birth weight to adult obesity. Int J Cancer 2003, 103:789-791.
18. Waterland R.A., Garza C. Potential mechanisms of metabolic imprinting that lead to chronic disease. Am J Clin Nutr 1999, 69:179-197.
19. Stover P.J., Caudill M.A. Genetic and epigenetic contributions to human nutrition and health: managing genome-diet interactions. J Am Diet Assoc 2008, 108:1480-1487.
20. Corella D., Ordovas J.M. Single nucleotide polymorphisms that influence lipid metabolism: interaction with dietary factors. Annu Rev Nutr 2005, 25:341-390.
21. Elliott R., Ong T.J. Nutritional genomics. BMJ 2002, 324:1438-1442.
22. van Ommen B., Stierum R. Nutrigenomics: exploiting systems biology in the nutrition and health arena. Curr Opin Biotechnol 2002, 13:517.
23. Muller M., Kersten S. Nutrigenomics: goals and strategies. Nat Rev Genet 2003, 4:315-322.
24. Chávez A., Muñoz de Chávez M. Nutrigenomics in public health nutrition: short-term perspectives. Eur J Clin Nutr 2003, 57(Suppl 1):S97-S100.
25. Kritchevsky D. Diet and cancer: what's next?. J Nutr 2003, 133(Suppl 1):3827S-3829S.
26. Holtzman N.A. Genetic variation in nutritional requirements and susceptibility to disease: policy implications. Am J Clin Nutr 1988, 48:1510-1516.
27. Hegele R.A., Jugenberg M., Connelly P.W., Jenkins D.J.A. Evidence for gene-diet interaction in the response of blood pressure to dietary fibre. Nutr Res 1997, 17:1229-1238.
28. Rapuri P.B., Gallagher J.C., Kinyamu H.K., Ryschon K.L. Caffeine intake increases the rate of bone loss in elderly women and interacts with vitamin D receptor genotypes. Am J Clin Nutr 2001, 74:694-700.
29. Rapuri P.B., Gallagher J.C., Nawaz Z. Caffeine decreases vitamin D receptor protein expression and 1,25(OH)2D3 stimulated alkaline phosphatase activity in human osteoblast cells. J Steroid Biochem Mol Biol 2007, 103:368-371.
30. Barrett-Connor E., Chang J.C., Edelstein S.L. Coffee-associated osteoporosis offset by daily milk consumption. The Rancho Bernardo study. JAMA 1994, 271:280-283.
31. Harris S.S., Dawson-Hughes B. Caffeine and bone loss in healthy postmenopausal women. Am J Clin Nutr 1994, 60:573-578.
32. Cummings S.R., Nevitt M.C., Browner W.S., Stone K., Fox K.M., Ensrud K.E., et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995, 332:767-773.
33. Kiel P., Felson D.T., Hannan M.T., Anderson J.J., Wilson P.W. Caffeine and the risk of hip fracture: the Framingham study. Am J Epidemiol 1990, 132:675-684.
34. Ingles S.A., Wang J., Coetzee G.A., Lee E.R., Frankl H.D., Haile R.W. Vitamin D receptor polymorphisms and risk of colorectal adenomas (United States). Cancer Causes Control 2001, 12:607-614.
35. Lowe L.C., Guy M., Mansi J.L., Peckitt C., Bliss J., Wilson R.G., et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 2005, 41:1164-1169.
36. Grundberg E., Brändström H., Ribom E.L., Ljunggren O., Kindmark A., Mallmin H. A poly adenosine repeat in the human vitamin D receptor gene is associated with bone mineral density in young Swedish women. Calcif Tissue Int 2003, 73(5):455-462. [Epub 2003 Sep 10].
37. Ferrari S.L. Osteoporosis, vitamin D receptor gene polymorphisms and response to diet. World Rev Nutr Diet 2001, 89:83-92.
38. Graafmans W.C., Lips P., Ooms M.E., van Leeuwen J.P., Pols H.A., Uitterlinden A.G. The effect of vitamin D supplementation on the bone mineral density of the femoral neck is associated with vitamin D receptor genotype. J Bone Miner Res 1997, 12:1241-1245.
39. Juo S.H., Wyszynski D.F., Beaty T.H., Huang H.Y., Bailey-Wilson J.E. Mild association between the A/G polymorphism in the promoter of the apolipoprotein A-I gene and apolipoprotein A-I levels: a meta-analysis. Am J Med Genet 1999, 82:235-241.
40. Matsunaga A., Sasaki J., Han H., Huang W., Kugi M., Koga T., et al. Compound heterozygosity for an apolipoprotein A1 gene promoter mutation and a structural nonsense mutation with apolipoprotein A1 deficiency. Arterioscler Thromb Vasc Biol 1999, 19:348-355.
41. Pagani F., Sidoli A., Giudici G.A., Barenghi L., Vergani C., Baralle F.E. Human apolipoprotein A-I gene promoter polymorphism: association with hyperalphalipoproteinemia. J Lipid Res 1990, 31:1371-1377.
42. Meng Q.H., Pajukanta P., Valsta L., Aro A., Pietinen P., Tikkanen M.J. Influence of apolipoprotein A-1 promoter polymorphism on lipid levels and responses to dietary change in Finnish adults. J Intern Med 1997, 241:373-378.
43. Paul-Hayase H., Rosseneu M., Robinson D., Van Bervliet J.P., Deslypere J.P., Humphries S.E. Polymorphisms in the apolipoprotein (apo) AI-CIII AIV gene cluster: detection of genetic variation determining plasma apo AI, apo CIII and apo AIV concentrations. Hum Genet 1992, 88:439-446.
44. Mata P., Lopez-Miranda J., Pocovi M., Alonso R., Lahoz C., Marin C., et al. Human apolipoprotein A-I gene promoter mutation influences plasma low density lipoprotein cholesterol response to dietary fat saturation. Atherosclerosis 1998, 137:367-376.
45. Ordovas J.M., Corella D., Cupples L.A., Demissie S., Kelleher A., Coltell O., et al. Polyunsaturated fatty acids modulate the effects of the APOA1 G-A polymorphism on HDL cholesterol concentrations in a sex-specific manner: the Framingham Study. Am J Clin Nutr 2002, 75:38-46.
46. Duivenvoorden I., Teusink B., Rensen P.C., Romijn J.A., Havekes L.M., Voshol P.J. Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice. Diabetes 2005, 54(3):664-671.
47. Minihane A.M., Finnegan Y.E., Talmud P., Leigh-Firbank E.C., Williams C.M. Influence of the APOC3 - 2854T>G polymorphism on plasma lipid levels: effect of age and gender. Biochim Biophys Acta 2002, 1583(3):311-314.
48. Chmielewski M., Stenvinkel P., Luttropp K., Suliman M.E., Qureshi A.R., Carrero J.J., et al. Lipoprotein lipase 1595 c/g and hepatic lipase - 480 c/t polymorphisms - impact on lipid profile in incident dialysis patients. Blood Purif 2008, 26:555-560.
49. Ordovas J.M., Mooser V. Nutrigenomics and nutrigenetics. Curr Opin Lipidol 2004, 15:101-108.
50. Soriguer F., Morcillo S., Cardona F., Rojo-Martinez G., de la Cruz Almaraz M., Ruiz de Adana Mde L., et al. Pro12Ala polymorphism of the PPARG2 gene is associated with type 2 diabetes mellitus and peripheral insulin sensitivity in a population with a high intake of oleic acid. J Nutr 2006, 136:2325-2330.
51. Li H., Kantoff P.W., Giovannucci E., Leitzmann M.F., Gaziano J.M., Stampfer M.J., et al. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 2005, 65:2498-2504.
52. Palli D., Masala G., Peluso M., Gaspari L., Krogh V., Munnia A., et al. The effects of diet on DNA bulky adduct levels are strongly modified by GSTM1 genotype: a study on 634 subjects. Carcinogenesis 2004, 25:577-584.
53. Lampe J.W., Chen C., Li S., Prunty J., Grate M.T., Meehan D.E., et al. Modulation of human glutathione S-transferases by botanically defined vegetable diets. Cancer Epidemiol Biomarkers Prev 2000, 9:787-793.
54. Brennan P., Hsu C.C., Moullan N., Szeszenia-Dabrowska N., Lissowska J., Zaridze D., et al. Effect of cruciferous vegetables on lung cancer in patients stratified by genetic status: a mendelian randomisation approach. Lancet 2005, 366:1558-1560.
55. Grimble R.F., Howell W.M., O'Reilly G., Turner S.J., Markovic O., Hirrell S., et al. The ability of fish oil to suppress tumor necrosis factor alpha production by peripheral blood mononuclear cells in healthy men is associated with polymorphisms in genes that influence tumor necrosis factor alpha production. Am J Clin Nutr 2002, 76:454-459.
56. Duarte I., Santos A., Sousa H., Catarino R., Pinto D., Matos A., et al. G-308A TNF-alpha polymorphism is associated with an increased risk of invasive cervical cancer. Biochem Biophys Res Commun 2005, 334:588-592.
57. van den Berg S.W., Dollé M.E., Imholz S., van der A.D.L., van 't Slot R., Wijmenga C., et al. Genetic variations in regulatory pathways of fatty acid and glucose metabolism are associated with obesity phenotypes: a population-based cohort study. Int J Obes (Lond) 2009, 33:1143-1152.
58. Ashfield-Watt P.A., Pullin C.H., Whiting J.M., Clark Z.E., Moat S.J., Newcombe R.G., et al. Methylenetetrahydrofolate reductase 677C{combining right arrow above}T genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement: a randomized controlled trial. Am J Clin Nutr 2002, 76:180-186.
59. Kardia S.L. Context-dependent genetic effects in hypertension. Curr Hypertens Rep 2000, 2:32-38.
60. Yang R.C. Epistasis of quantitative trait loci under different gene action models. Genetics 2004, 167:1493-1505.
61. Erdman J.W., Ford N.A., Lindshield B.L. Are the health attributes of lycopene related to its antioxidant function?. Arch Biochem Biophys 2008.
62. Seppo L., Jauhiainen T., Poussa T., Korpela R. A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am J Clin Nutr 2003, 77:326-330.
63. Fujita H., Yokoyama K., Yoshikawa M. Classification and antihypertensive activity of angiotensin I-converting enzyme inhibitory peptides derived from food proteins. J Food Sci 2000, 65:564-569.
64. Chen H.M., Muramoto K., Yamauchi F., Nokihara K. Antioxidant activity of designed peptides based on the antioxidative peptide isolated from digests of a soybean protein. J Agric Food Chem 1996, 44:2619-2623.
65. Clarke S.D. Nutrient regulation of gene and protein expression. Curr Opin Clin Nutr Metab Care 1999, 2:287-289.
66. Moazed D. Enzymatic activities of Sir2 and chromatin silencing. Curr Opin Cell Biol 2001, 13:232-238.
67. Aagaard-Tillery K.M., Grove K., Bishop J., Ke X., Fu Q., McKnight R., et al. Developmental origins of disease and determinants of chromatin structure: maternal diet modifies the primate fetal epigenome. J Mol Endocrinol 2008, 41:91-102.
68. Ross S.A. Diet and DNA methylation interactions in cancer prevention. Ann N Y Acad Sci 2003, 983:197-207.
69. Davis C.D., Uthus E.O. DNA methylation, cancer susceptibility, and nutrient interactions. Exp Biol Med (Maywood) 2004, 229:988-995.
70. Freudenheim J.L., Bonner M., Krishnan S., Ambrosone C.B., Graham S., McCann S.E., et al. Diet and alcohol consumption in relation to p53 mutations in breast tumors. Carcinogenesis 2004, 25:931-939.
71. Munaka M., Kohshi K., Kawamoto T., Takasawa S., Nagata N., Itoh H., et al. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. J Cancer Res Clin Oncol 2003, 129:355-360.
72. Davis C.D., Uthus E.O., Finley J.W. Dietary selenium and arsenic affect DNA methylation in vitro in Caco-2 cells and in vivo in rat liver and colon. J Nutr 2000, 130:2903-2909.
73. Steinmetz K.L., Pogribny I.P., James S.J., Pitot H.C. Hypomethylation of the rat glutathione S-transferase pi (GSTP) promoter region isolated from methyl-deficient livers and GSTP-positive liver neoplasm. Carcinogenesis 1998, 19:1487-1494.
74. Giovannucci E., Chen J., Smith-Warner S.A., Rimm E.B., Fuchs C.S., Palomeque C., et al. Methylenetetrahydrofolate reductase, alcohol dehydrogenase, diet, and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2003, 12:970-979.
75. Day J.K., Bauer A.M., desBordes C., Zhuang Y., Kim B.-E., Newton L.G., et al. Genistein alters methylation patterns in mice. J Nutr 2002, 132:2419S-2423S.
76. Kune G., Watson L. Colorectal cancer protective effects and the dietary micronutrients folate, methionine, vitamins B6, B12, C, E, selenium, and lycopene. Nutr Cancer 2006, 56:11-21.
77. Cooney C.A., Dave A.A., Wolff G.L. Maternal methyl supplements in mice affect epigenetic variation and DNA methylation of offspring. J Nutr 2002, 132:2393S-2400S.
78. Lee Y.W., Klein C.B., Kargacin B., Salnikow K., Kitahara J., Dowjat K., et al. Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation: a new model for epigenetic carcinogens. Mol Cell Biol 1995, 15:2547-2557.
79. Broday L., Peng W., Kuo M.H., Salnikow K., Zoroddu M., Costa M. Nickel compounds are novel inhibitors of histone H4 acetylation. Cancer Res 2000, 60:238-241.
80. Davis C.D., Uthus E.O. Dietary folate and selenium affect dimethylhydrazine-induced aberrant crypt formation, global DNA methylation and one-carbon metabolism in rats. Nutr 2003, 133:2907-2914.
81. Evenson J.K., Wheeler A.D., Blake S.M., Sunde R.A. Selenoprotein mRNA is expressed in blood at levels comparable to major tissues in rats. J Nutr 2004, 134:2640-2645.
82. Hesketh J. Nutrigenomics and selenium: gene expression patterns, physiological targets, and genetics. Annu Rev Nutr 2008, 28:157-177.
83. Harnack L., Jacobs D.R., Nicodemus K., Lazovich D., Anderson K., Folsom A.R. Relationship of folate, vitamin B-6, vitamin B-12, and methionine intake to incidence of colorectal cancers. Nutr Cancer 2002, 43:152-158.
84. Fuchs C.S., Willett W.C., Colditz G.A., Hunter D.J., Stampfer M.J., Speizer F.E., et al. The influence of folate and multivitamin use on the familial risk of colon cancer in women. Cancer Epidemiol Biomarkers Prev 2002, 11:227-234.
85. Zeng X., Rao M.S. Controlled genetic modification of stem cells for developing drug discovery tools and novel therapeutic applications. Curr Opin Mol Ther 2008, 10:207-213.
86. Cooney C.A. Are somatic cells inherently deficient in methylation metabolism? A proposed mechanism for DNA methylation loss, senescence and aging. Growth Dev Aging 1993, 57:261-273.
87. Knouff C., Auwerx J. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 2004, 25:899-918.
88. Robinson-Rechavi M., Carpentier A.S., Duffraisse M., Laudet V. How many nuclear hormone receptors are there in the human genome?. Trends Genet 2001, 17:554-556.
89. Francis G.A., Fayard E., Picard F., Auwerx J. Nuclear receptors and the control of metabolism. Annu Rev Physiol 2003, 65:261-311.
90. Mukherjee R., Jow L., Croston G.E., Paterniti J.R. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997, 272:8071-8076.
91. Sabatino L., Casamassimi A., Peluso G., Barone M.V., Capaccio D., Migliore C., et al. A novel peroxisome proliferator-activated receptor gamma isoform with dominant negative activity generated by alternative splicing. J Biol Chem 2005, 280:26517-26525.
92. Muller Y.L., Bogardus C., Beamer B.A., Shuldiner A.R., Baier L.J. A functional variant in the peroxisome proliferator-activated receptor gamma2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians. Diabetes 2003, 52:1864-1871.
93. Costa V., Casamassimi A., Esposito K., Villani A., Capone M.E., Iannella R., et al. Characterization of a novel polymorphism in PPARG regulatory region associated with type 2 diabetes and diabetic retinopathy in Italy. J Biomed Biotech 2008, [in press].
94. Rosen E.D., Spiegelman B.M. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001, 276:37731-37734.
95. Hasstedt S.J., Ren Q.F., Teng K., Elbein S.C. Effect of the peroxisome proliferator-activated receptor-gamma 2 pro(12)ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. J Clin Endocrinol Metab 2001, 86:536-541.
96. Deeb S., Fajas L., Nemoto M., Laakso M., Fujimoto W., Auwerx J. A Pro 12 Ala substitution in the human peroxisome proliferator-activated receptor 2 is associated with decreased receptor activity, improved insulin sensitivity, and lowered body mass index. Nat Genet 1998, 20:284-287.
97. Altshuler D., Hirschhorn J.N., Klannemark M., Lindgren C.M., Vohl M.C., Nemesh J., et al. The common PPAR Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000, 26:76-80.
98. Pihlajamaki J., Miettinen R., Valve R., Karjalainen L., Mykkanen L., Kuusisto J., et al. The Pro12A1a substitution in the peroxisome proliferator activated receptor 2 is associated with an insulin-sensitive phenotype in families with familial combined hyperlipidemia and in nondiabetic elderly subjects with dyslipidemia. Atherosclerosis 2000, 151:567-574.
99. Mori H., Ikegami H., Kawaguchi Y., Seino S., Yokoi N., Takeda J., et al. The Pro12Ala substitution in PPAR-γ is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001, 50:891-894.
100. Lindi V.I., Uusitupa M.I., Lindstrom J., Louheranta A., Eriksson J.G., Valle T.T., et al. Association of the Pro12Ala polymorphism in the PPAR-2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 2002, 51:2581-2586.
101. Ridker P.M., Cook N.R., Cheng S., Erlich H.A., Lindpaintner K., Plutzky J., et al. Alanine for proline substitution in the peroxisome proliferator-activated receptor-2 (PPAR 2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol 2003, 23:859-863.
102. Mancini F.P., Vaccaro O., Sabatino L., Tufano A., Rivellese A.A., Riccardi G., et al. Pro12Ala substitution in the peroxisome proliferator-activated receptor-2 is not associated with type 2 diabetes. Diabetes 1999, 48:1466-1468.
103. Swarbrick M.M., Chapman C.M., McQuillan B.M., Hung J., Thompson P.L., Beilby J.P.A. Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-2 is associated with combined hyperlipidaemia in obesity. Eur J Endocrinol 2001, 144:277-282.
104. Valve R., Sivenius K., Miettinen R., Pihlajamaki J., Rissanen A., Deeb S.S., et al. Two polymorphisms in the peroxisome proliferator-activated receptor-gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 1999, 84:3708-3712.
105. Beamer B.A., Yen C.J., Andersen R.E., Muller D., Elahi D., Cheskin L.J., et al. Association of the Pro12Ala variant in peroxisome proliferator-activated receptor 2 gene with obesity in two Caucasian populations. Diabetes 1998, 47:1806-1808.
106. Robitaille J., Despres J.P., Perusse L., Vohl M.C. The PPAR-P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Quebec Family Study. Clin Genet 2003, 63:109-116.
107. Kolehmainen M., Uusitupa M.I., Alhava E., Laakso M., Vidal H. Effect of the Pro12Ala polymorphism in the peroxisome proliferator-activated receptor (PPAR) 2 gene on the expression of PPAR target genes in adipose tissue of massively obese subjects. J Clin Endocrinol Metab 2003, 88:1717-1722.
108. Stumvoll M., Haring H. The peroxisome proliferator-activated receptor-2 Pro12Ala polymorphism. Diabetes 2002, 51:2341-2347.
109. Doney A., Fischer B., Frew D., Cumming A., Flavell D.M., World M., et al. Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet 2002, 3:21.
110. Cecil J.E., Watt P., Palmer C.N., Hetherington M. Energy balance and food intake: the role of PPARgamma gene polymorphisms. Physiol Behav 2006, 88:227-233.
111. Zhang B., Berger J., Hu E., Szalkowski D., White-Carrington S., Spiegelman B.M., et al. Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. Mol Endocrinol 1996, 10:1457-1466.
112. Ideker T., Galitski T., Hood L. A new approach to decoding life: systems biology. Annu Rev Genomics Hum Genet 2001, 2:343-372.
113. Jansen B.J., Schalkwijk J. Transcriptomics and proteomics of human skin. Brief Funct Genomic Proteomic 2003, 1:326-341.
114. Collins F.S. Genome research: the next generation. Cold Spring Harb Symp Quant Biol 2003, 68:49-54.
115. Daniel H. Genomics and proteomics: importance for the future of nutrition research. Br J Nutr 2002, 87(Suppl 2):S305-S311.
116. Mooser V., Ordovas J.M. 'Omic' approaches and lipid metabolism: are these new technologies holding their promises?. Curr Opin Lipidol 2003, 14:115-119.
117. Cobb J.P., Mindrinos M.N., Miller-Graziano C., Calvano S.E., Baker H.V., Xiao W., et al. Inflammation and Host Response to Injury Large-Scale Collaborative Research Program. Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci U S A 2005, 102:4801-4806.
118. Kussmann M., Rezzi S., Daniel H. Profiling techniques in nutrition and health research. Curr Opin Biotechnol 2008, 19:83-99.
119. Thimmulappa R.K., Mai K.H., Srisuma S., Kensler T.W., Yamamoto M., Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 2002, 62:5196-5203.
120. Trujillo E., Davis C., Milner J. Nutrigenomics, proteomics, metabolomics, and the practice of dietetics. J Am Diet Assoc 2006, 106:403-413.
121. Pan D.A., Mater M.K., Thelen A.P., Peters J.M., Gonzalez F.J., Jump D.B. Evidence against the peroxisome proliferator-activated receptor alpha (PPARalpha) as the mediator for polyunsaturated fatty acid suppression of hepatic l-pyruvate kinase gene transcription. J Lipid Res 2000, 41:742-751.
122. Yang R.L., Li W., Shi Y.H., Le G.W. Lipoic acid prevents high-fat diet-induced dyslipidemia and oxidative stress: a microarray analysis. Nutrition 2008, 24:582-588.
123. van Erk M.J., Blom W.A., van Ommen B., Hendriks H.F. High-protein and high-carbohydrate breakfasts differentially change the transcriptome of human blood cells. Am J Clin Nutr 2006, 84:1233-1241.
124. Salvatore P., Casamassimi A., Sommese L., Fiorito C., Ciccodicola A., Rossiello R., et al. Detrimental effects of Bartonella henselae are counteracted by l-arginine and nitric oxide in human endothelial progenitor cells. Proc Natl Acad Sci U S A 2008, 105:9427-9432.
125. Crujeiras A.B., Parra D., Milagro F.I., Goyenechea E., Larrarte E., Margareto J., et al. Differential expression of oxidative stress and inflammation related genes in peripheral blood mononuclear cells in response to a low-calorie diet: a nutrigenomics study. OMICS 2008, 12:251-261.
126. Bouwens M., Afman L.A., Muller M. Fasting induces changes in peripheral blood mononuclear cell gene expression profiles related to increases in fatty acid b-oxidation: functional role of peroxisome proliferator activated receptor a in human peripheral blood mononuclear cells. Am J Clin Nutr 2007, 86:1515-1523.
127. Ashrafi K., Chang F.Y., Watts J.L., Fraser A.G., Kamath R.S., Ahringer J., et al. Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature 2003, 421:268-272.
128. Singh S.V., Srivastava S.K., Choi S., Lew K.L., Antosiewicz J., Xiao D., et al. Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J Biol Chem 2005, 280:19911-19924.
129. Wilkins M.R., Sanchez J.C., Gooley A.A., Appel R.D., Humphery-Smith I., Hochstrasser D.F., et al. Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev 1996, 13:19-50.
130. Glynne R., Ghandour G., Rayner J., Mack D.H., Goodnow C.C. B-lymphocyte quiescence, tolerance and activation as viewed by global gene expression profiling on microarrays. Immunol Rev 2000, 176:216-246.
131. Amundson S.A., Myers T.G., Scudiero D., Kitada S., Reed J.C., Fornace A.J. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000, 60:6101-6110.
132. tom Dieck H., Döring F., Fuchs D., Roth H.P., Daniel H Transcriptome and proteome analysis identifies the pathways that increase hepatic lipid accumulation in zinc-deficient rats. J Nutr 2005, 135:199-205.
133. Breikers G., van Breda S.G., Bouwman F.G., van Herwijnen M.H., Renes J., Mariman E.C., et al. Potential protein markers for nutritional health effects on colorectal cancer in the mouse as revealed by proteomics analysis. Proteomics 2006, 6:2844-2852.
134. Virgili F., Perozzi G. How does Nutrigenomics impact human health?. IUBMB Life 2008, 60:341-344.
135. Sutton K.H. Nutrigenomics New Zealand. Considerations for the successful development and launch of personalised nutrigenomic foods. Mutat Res 2007, 622:117-121.
136. Pearson H. Genetic testing for everyone. Nature 2008, 453:570-571.
137. Ferguson H.R., Wild C.P., Anderson L.A., Murphy S.J., Johnston B.T., Murray L.J., Watson R.G., et al. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2008, 17:727-731.
138. Steiner C., Arnould S., Scalbert A., Manach C. Isoflavones and the prevention of breast and prostate cancer: new perspectives opened by nutrigenomics. Br J Nutr 2008, 99(E Suppl 1):ES78-ES108.
139. Kornman K., Rogus J., Roh-Schmidt H., Krempin D., Davies A.J., Grann K., et al. Interleukin-1 genotype-selective inhibition of inflammatory mediators by a botanical: a nutrigenetics proof of concept. Nutrition 2007, 23:844-852.
140. Arkadianos I., Valdes A.M., Marinos E., Florou A., Gill R.D., Grimaldi K.A. Improved weight management using genetic information to personalize a calorie controlled diet. Nutr J 2007, 6:29.
141. Levy S., Strausberg R.L. Human genetics: individual genomes diversify. Nature 2008, 456:49-51.
142. Redon R., Ishikawa S., Fitch K.R., Feuk L., Perry G.H., Andrews T.D., et al. Global variation in copy number in the human genome. Nature 2006, 444:444-454.
143. Iafrate A.J., Feuk L., Rivera M.N., Listewnik M.L., Donahoe P.K., Qi Y., et al. Detection of large-scale variation in the human genome. Nat Genet 2004, 36:949-951.
144. Sebat J., Lakshmi B., Troge J., Alexander J., Young J., Lundin P., et al. Large-scale copy number polymorphism in the human genome. Science 2004, 305:525-528.
145. Sharp A.J., Locke D.P., McGrath S.D., Cheng Z., Bailey J.A., Vallente R.U., et al. Segmental duplications and copy-number variation in the human genome. Am J Hum Genet 2005, 77:78-88.
146. Conrad D.F., Andrews T.D., Carter N.P., Hurles M.E., Pritchard J.K. A high-resolution survey of deletion polymorphism in the human genome. Nat Genet 2006, 38:75-81.
147. Feuk L., Marshall C.R., Wintle R.F., Scherer S.W. Structural variants: changing the landscape of chromosomes and design of disease studies. Hum Mol Genet 2006, 15(Spec No 1):R57-R66.
148. Feuk L., Carson A.R., Scherer S.W. Structural variation in the human genome. Nat Rev Genet 2006, 7:85-97.
149. Freeman J.L., Perry G.H., Feuk L., Redon R., McCarroll S.A., Altshuler D.M., et al. Copy number variation: new insights in genome diversity. Genome Res 2006, 16:949-961.
150. Tuzun E., Sharp A.J., Bailey J.A., Kaul R., Morrison V.A., Pertz L.M., et al. Fine-scale structural variation of the human genome. Nat Genet 2005, 37:727-732.
151. Korbel J.O., Urban A.E., Grubert F., Du J., Royce T.E., Starr P., et al. Systematic prediction and validation of breakpoints associated with copy-number variants in the human genome. Proc Natl Acad Sci U S A 2007, 104:10110-10115.
152. Mileyko Y., Joh R.I., Weitz J.S. Small-scale copy number variation and large-scale changes in gene expression. Proc Natl Acad Sci U S A 2008, 105:16659-16664.
153. Barber J.C., Maloney V., Hollox E.J., Stuke-Sontheimer A., du Bois G., Daumiller E., et al. Duplications and copy number variants of 8p23.1 are cytogenetically indistinguishable but distinct at the molecular level. Eur J Hum Genet 2005, 13:1131-1136.
154. Shelling A.N., Ferguson L.R. Genetic variation in human disease and a new role for copy number variants. Mutat Res 2007, 622:33-41.
155. Perry G.H., Dominy N.J., Claw K.G., Lee A.S., Fiegler H., Redon R., et al. Diet and the evolution of human amylase gene copy number variation. Nat Genet 2007, 39:1256-1260.
156. Groot P.C., Bleeker M.J., Pronk J.C., Arwert F., Mager W.H., Planta R.J., et al. The human alpha-amylase multigene family consists of haplotypes with variable numbers of genes. Genomics 1989, 5:29-42.
157. Kaput J. Decoding the pyramid: a systems-biological approach to nutrigenomics. Ann N Y Acad Sci 2005, 1055:64-79.